Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 15, 2025.

By Lori Solomon HealthDay Reporter

THURSDAY, May 15, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity, according to a study published online May 11 in eClinicalMedicine.

Yael Wolff Sagy, Ph.D., from Clalit Health Services in Tel-Aviv, Israel, and colleagues conducted an observational, retrospective cohort study based on electronic medical records data to compare the incidence of ORC in adults (≥24 years) living with obesity and diabetes who were treated with a first-generation GLP-1 RA or with bariatric metabolic surgery (BMS). Analysis included 3,178 matched pairs.

The researchers found that over a median of 7.5 years, ORC occurred in 5.62 cases per 1,000 person-years in the BMS group and in 5.89 cases per 1,000 person-years in the GLP-1 RA group (adjusted hazard ratio for GLP-1 RA versus BMS, 1.11; 95 percent confidence interval, 0.86 to 1.44). Assessment of mediation through weight loss had an estimated direct effect of 41 percent relative risk reduction of the pharmacotherapy.

"The estimated direct effect of GLP-1 RA versus BMS on the risk for ORC may point at additional pathways beyond weight loss in which GLP-1 RAs contribute to the decreased risk for ORC, such as reducing inflammation," the authors write. "However, future studies are needed to validate the observed effects and explore the underlying mechanisms."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-16 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords